Slingshot members are tracking this event:
Merck’s KEYTRUDA (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
Slingshot Insights Explained
Aug 02, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Keytruda, Pembrolizumab, European Commission, Advanced Non-small Cell Lung Cancer, Nsclc, Tumor, Pd-l1, Keynote-010, Chemotherapy